Egetis Therapeutics AB (publ) announced that it has received a Promising Innovative Medicine (PIM) designation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the investigational drug Emcitate® (tiratricol) in the treatment of monocarboxylate transporter 8 (MCT8) deficiency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.49 SEK | -3.13% |
|
-3.85% | -19.53% |
20/06 | Transcript : Egetis Therapeutics AB - Special Call | |
19/06 | Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.53% | 125M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- EGTX Stock
- News Egetis Therapeutics AB
- Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency